לקמבי - Leqembi
×××ר××
×צפ××× ×××××¢ ××ר×× ×ר×פ××× ×ש ××××× ×¡ ××ש××× ×. ×× ××× × ×¨×©×× ××× ×¡ ××רש×× ×ר×פ××× ××× ×©× ×קצ××¢×ת רפ×××××.
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | N06DX Other anti-dementia drugs |
|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | ת××-×ר××× - I.V |
| צ×רת ××× ×× | תר××× ×××× ×ª ת×××¡× ×××× ×¤××××, CONCENTRATE FOR SOLUTION FOR INFUSION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | LEQEMBI is indicated for the treatment of Alzheimerâs disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. |
| ×ת××××ת × ×× | Contraindications |
| ש×××ש ×××ר××× ××× ×§× | Pregnancy and Lactation |
| פר×ק×××× ×××§× | Pharmacodynamic Properties |
| פר×ק×ק×× ×××§× | Pharmacokinetic Properties |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  |
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ×ק××× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | EISAI EUROPE LTD, UK |
| ×©× ××¢× ×ר×ש×× | EISAI ISRAEL LTD., ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 6/2023. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 26/08/2024 |
השינוי האחרון נעשה בֹ־29 בנובמבר 2024 ב־11:42